Search

Your search keyword '"Sartor, A. Oliver"' showing total 425 results
Start Over Author "Sartor, A. Oliver"
425 results on '"Sartor, A. Oliver"'

1. External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial

Author

Ross, Ashley E., Zhang, Jingbin, Huang, Huei-Chung, Yamashita, Rikiya, Keim-Malpass, Jessica, Simko, Jeffry P., DeVries, Sandy, Morgan, Todd M., Souhami, Luis, Dobelbower, Michael C., McGinnis, L. Scott, Jones, Christopher U., Dess, Robert T., Zeitzer, Kenneth L., Choi, Kwang, Hartford, Alan C., Michalski, Jeff M., Raben, Adam, Gomella, Leonard G., Sartor, A. Oliver, Rosenthal, Seth A., Sandler, Howard M., Spratt, Daniel E., Pugh, Stephanie L., Mohamad, Osama, Esteva, Andre, Chen, Emmalyn, Schaeffer, Edward M., Tran, Phuoc T., and Feng, Felix Y.

Published
2024
Full Text
View/download PDF

2. Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

Author

Higano, Celestia S, Armstrong, Andrew J, Sartor, A Oliver, Vogelzang, Nicholas J, Kantoff, Philip W, McLeod, David G, Pieczonka, Christopher M, Penson, David F, Shore, Neal D, Vacirca, Jeffrey, Concepcion, Raoul S, Tutrone, Ronald F, Nordquist, Luke T, Quinn, David I, Kassabian, Vahan, Scholz, Mark C, Harmon, Matt, Tyler, Robert C, Chang, Nancy N, Tang, Hong, and Cooperberg, Matthew R

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Prostate Cancer, Urologic Diseases, Aging, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Humans, Male, Neoplasm Metastasis, Prospective Studies, Prostatic Neoplasms, Castration-Resistant, Registries, Tissue Extracts, immunotherapy, overall survival, prostate cancer, safety, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundThe large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).MethodsPROCEED enrolled patients with mCRPC receiving 3 biweekly sipuleucel-T infusions. Assessments included overall survival (OS), serious adverse events (SAEs), cerebrovascular events (CVEs), and anticancer interventions (ACIs). Follow-up was for ≥3 years or until death or study withdrawal.ResultsIn 2011-2017, 1976 patients were followed for 46.6 months (median). The median age was 72 years, and the baseline median prostate-specific antigen level was 15.0 ng/mL; 86.7% were white, and 11.6% were African American. Among the patients, 1902 had 1 or more sipuleucel-T infusions. The median OS was 30.7 months (95% confidence interval [CI], 28.6-32.2 months). Known prognostic factors were independently associated with OS in a multivariable analysis. Among the 1255 patients who died, 964 (76.8%) died of prostate cancer (PC) progression. The median time from the first infusion to PC death was 42.7 months (95% CI, 39.4-46.2 months). The incidence of sipuleucel-T-related SAEs was 3.9%. The incidence of CVEs was 2.8%, and the rate per 100 person-years was 1.2 (95% CI, 0.9-1.6). The CVE incidence among 11,972 patients with mCRPC from the Surveillance, Epidemiology, and End Results-Medicare database was 2.8%; the rate per 100 person-years was 1.5 (95% CI, 1.4-1.7). One or more ACIs (abiraterone, enzalutamide, docetaxel, cabazitaxel, or radium 223) were received by 77.1% of the patients after sipuleucel-T; 32.5% and 17.4% of the patients experienced 1- and 2-year treatment-free intervals, respectively.ConclusionsPROCEED provides contemporary survival data for sipuleucel-T-treated men in a real-world setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials with sipuleucel-T. The safety and tolerability of sipuleucel-T in PROCEED were consistent with previous findings.

Published
2019

3. SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer.

Author

Johnson, Geoffrey, primary, Lengyelova, Eva, additional, Nordquist, Luke, additional, Prasad, Vikas, additional, Anderson, Monique, additional, Gervasio, Othon, additional, Parker, Michelle, additional, Miller, Robert M., additional, Sartor, A. Oliver, additional, and Tagawa, Scott T., additional

Published
2024
Full Text
View/download PDF

4. Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).

Author

Tagawa, Scott T., primary, Thomas, Charlene, additional, Nauseef, Jones T., additional, Sartor, A. Oliver, additional, Sun, Michael Philip, additional, Huicochea Castellanos, Sandra, additional, Ricaurte Fajardo, Andres, additional, Beltran, Himisha, additional, Demichelis, Francesca, additional, Sigouros, Michael, additional, Orlando, Francesco, additional, Molina, Ana M., additional, Davidson, Zachary, additional, Patel, Amie, additional, Lewis, Brian E., additional, Nanus, David M., additional, Vallabhajosula, Shankar, additional, Bander, Neil Harrison, additional, and Osborne, Joseph, additional

Published
2024
Full Text
View/download PDF

5. Assessment of blood-based tumor mutational burden on clinical outcomes in advanced breast and prostate cancer treated with immune checkpoint inhibitors

Author

Barata, Pedro, primary, Barnett, Reagan, additional, Jang, Albert, additional, Lanka, Sree, additional, Fu, Pingfu, additional, Bucheit, Leslie, additional, Babiker, Hani, additional, Bryce, Alan, additional, Meyer, Haley, additional, Choi, Yujin, additional, Moore, Casey, additional, Garje, Rohan, additional, Gao, Xin, additional, Kim, Dae, additional, Chang, Richard, additional, Gulhati, Pat, additional, Ramaker, Ryne, additional, Bansal, Rani, additional, Zhang, Tian, additional, Armstrong, Andrew, additional, Bilen, Mehmet, additional, and Sartor, Alton Oliver, additional

Published
2024
Full Text
View/download PDF

6. The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521

Author

Hall, William A., Karrison, Theodore G., Rosenthal, Seth A., Amin, Mahul B., Gomella, Leonard G., Purdy, James A., Sartor, A. Oliver, Michalski, Jeff M., Garzotto, Mark G., Bergom, Carmen, Jani, Ashesh B., Lawton, Colleen A.F., Simko, Jeffry P., Moore, Joan K., Gore, Elizabeth M., Lee, W. Robert, Nguyen, Paul L., Danielson, Brita L., Sandler, Howard M., and Feng, Felix Y.

Published
2022
Full Text
View/download PDF

7. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer

Author

Reyes, Diane K., Trock, Bruce J., Tran, Phuoc T., Pavlovich, Christian P., Deville, Curtiland, Allaf, Mohamad E., Greco, Stephen C., Song, Daniel Y., Bivalacqua, Trinity J., Han, Misop, Partin, Alan W., Sartor, A. Oliver, Rowe, Steven P., and Pienta, Kenneth J.

Published
2022
Full Text
View/download PDF

9. Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591.

Author

Tagawa, Scott T., Thomas, Charlene, Sartor, A. Oliver, Sun, Michael, Stangl-Kremser, Judith, Bissassar, Mahelia, Vallabhajosula, Shankar, Castellanos, Sandra Huicochea, Nauseef, Jones T., Sternberg, Cora N., Molina, Ana, Ballman, Karla, Nanus, David M., Osborne, Joseph R., and Bander, Neil H.

Published
2024
Full Text
View/download PDF

11. Long-term results of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy.

Author

Lukka, Himu, Pugh, Stephanie L., Shipley, William U., Major, Pierre, Sartor, A. Oliver, Dayes, Ian S., Bahary, Jean-Paul, Efstathiou, Jason A., Pisansky, Thomas Michael, Zeitzer, Kenneth Lee, Lawton, Colleen Anne, Dess, Robert Timothy, Camarata, Andrew S, Balogh, Alexander G., Souhami, Luis, Rosenthal, Seth A., Seiferheld, Wendy, Feng, Felix Y, and Sandler, Howard M.

Published
2024
Full Text
View/download PDF

15. Prognostic value of PSMA-extracellular vesicles in oligometastatic castration-sensitive prostate cancer treated with stereotactic ablative radiotherapy: A multi-center observational study.

Author

Lucien, Fabrice, Andrews, Jack R., Kim, Yohan J, Horjeti, Edlira, Arafa, Ali, Sutera, Philip, De Bruycker, Aurélie, Mercier, Carole, Phillips, Ryan, Song, Daniel, Kiess, Ana Ponce, Ost, Piet, Tran, Phuoc T., Childs, Daniel S, Sartor, A. Oliver, Orme, Jacob, and Park, Sean Sunghun

Published
2024
Full Text
View/download PDF

17. Safety outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223 following external beam radiation therapy: REASSURE US subset.

Author

Sartor, A. Oliver, Conti, Peter, Taplin, Mary-Ellen, Song, Daniel, George, Saby, Tomaszewski, Jeffrey John, Sylvester, John, Mantz, Constantine Anastasios, Given, Robert, Brookland, Robert K., Meltzer, Jeffrey, Korn, Matthew J., Parkin, Jacqueline, Babajanyan, Svetlana, and Higano, Celestia S.

Published
2024
Full Text
View/download PDF

18. Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies

Author

Jang, Albert, primary, Lanka, Sree M., additional, Jaeger, Ellen B., additional, Lieberman, Alexandra, additional, Huang, Minqi, additional, Sartor, A. Oliver, additional, Mendiratta, Prateek, additional, Brown, Jason R., additional, Garcia, Jorge A., additional, Farmer, Tiffany, additional, Sudhaman, Sumedha, additional, Mahmood, Tamara, additional, Pajak, Natalia, additional, Calhoun, Mark, additional, Dutta, Punashi, additional, ElNaggar, Adam, additional, Liu, Minetta C., additional, and Barata, Pedro C., additional

Published
2023
Full Text
View/download PDF

19. Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer

Author

Taza, Fadi, Holler, Albert E., Fu, Wei, Wang, Hao, Adra, Nabil, Albany, Costantine, Ashkar, Ryan, Cheng, Heather H., Sokolova, Alexandra O., Agarwal, Neeraj, Kessel, Adam, Bryce, Alan, Nafissi, Nellie, Barata, Pedro, Sartor, A. Oliver, Bastos, Diogo, Smaletz, Oren, Berchuck, Jacob E., Taplin, Mary-Ellen, Aggarwal, Rahul, Sternberg, Cora N., Vlachostergios, Panagiotis J., Alva, Ajjai S., Su, Christopher, Marshall, Catherine H., and Antonarakis, Emmanuel S.

Published
2021
Full Text
View/download PDF

21. Genomic alterations in patients with prostate cancer with liver metastases.

Author

Casado, Crystal, primary, Caputo, Sydney, additional, Jaeger, Ellen B., additional, Jang, Albert, additional, Sweeney, Patrick L, additional, Lanka, Sree M, additional, Gupta, Kanika, additional, Pocha, Olivia, additional, Hawkins, Maddie, additional, Huang, Minqi, additional, Lieberman, Alexandra, additional, Schwartz, Jennifer, additional, Miller, Patrick, additional, Barata, Pedro C., additional, Layton, Jodi Lyn, additional, Lewis, Brian E., additional, Ledet, Elisa M., additional, and Sartor, A. Oliver, additional

Published
2023
Full Text
View/download PDF

22. Comparison of ctDNA between African American and Caucasian patients with CRPC post abiraterone and/or enzalutamide.

Author

Jang, Albert, primary, Huang, Minqi, additional, Casado, Crystal, additional, Caputo, Sydney, additional, Sweeney, Patrick L, additional, Lanka, Sree M, additional, Gupta, Kanika, additional, Pocha, Olivia, additional, Habibian, Nicholas, additional, Hawkins, Maddie, additional, Lieberman, Alexandra, additional, Schwartz, Jennifer, additional, Jaeger, Ellen B., additional, Miller, Patrick, additional, Layton, Jodi Lyn, additional, Barata, Pedro C., additional, Lewis, Brian E., additional, Ledet, Elisa M., additional, and Sartor, A. Oliver, additional

Published
2023
Full Text
View/download PDF

23. 68Ga-PSMA-11 patients with newly diagnosed and recurrent prostate cancer (Firefly Study): Preliminary results.

Author

Hawkins, Charlotte, primary, Pocha, Olivia, additional, Ledet, Elisa M., additional, Lieberman, Alexandra, additional, Schwartz, Jennifer, additional, Hawkins, Maddie, additional, Bhandari, Priya, additional, Barata, Pedro C., additional, Jaeger, Ellen B., additional, Layton, Jodi Lyn, additional, Lewis, Brian E., additional, Harris, Kendra Marie, additional, and Sartor, A. Oliver, additional

Published
2023
Full Text
View/download PDF

25. Utility of circulating tumor DNA in monitoring treatment response to immune checkpoint inhibitors in patients with advanced genitourinary cancers.

Author

Jang, Albert, primary, Jaeger, Ellen B., additional, Rauterkus, Grant, additional, Lieberman, Alexandra, additional, Huang, Minqi, additional, Lanka, Sree M, additional, Sudhaman, Sumedha, additional, Mahmood, Tamara, additional, Pajak, Natalia, additional, Calhoun, Mark, additional, Tlemcani, Kaoutar, additional, ElNaggar, Adam, additional, Liu, Minetta, additional, Lewis, Brian E., additional, Layton, Jodi Lyn, additional, Sartor, A. Oliver, additional, and Barata, Pedro C., additional

Published
2023
Full Text
View/download PDF

26. Characterization of ctDNA findings at the end of life in patients with prostate cancer.

Author

Gupta, Kanika, primary, Caputo, Sydney, additional, Casado, Crystal, additional, Jang, Albert, additional, Sweeney, Patrick L, additional, Lanka, Sree M, additional, Pocha, Olivia, additional, Hawkins, Maddie, additional, Lieberman, Alexandra, additional, Schwartz, Jennifer, additional, Miller, Patrick, additional, Jaeger, Ellen B., additional, Barata, Pedro C., additional, Layton, Jodi Lyn, additional, Lewis, Brian E., additional, Ledet, Elisa M., additional, and Sartor, A. Oliver, additional

Published
2023
Full Text
View/download PDF

27. Analysis of TP53 gain of function mutations in metastatic castration-resistant prostate cancer.

Author

Sweeney, Patrick L, primary, Lanka, Sree M, additional, Jang, Albert, additional, Gupta, Kanika, additional, Caputo, Sydney, additional, Casado, Crystal, additional, Huang, Minqi, additional, Pocha, Olivia, additional, Hawkins, Maddie, additional, Lieberman, Alexandra, additional, Schwartz, Jennifer, additional, Jaeger, Ellen B., additional, Miller, Patrick, additional, Barata, Pedro C., additional, Layton, Jodi Lyn, additional, Lewis, Brian E., additional, Ledet, Elisa M., additional, and Sartor, A. Oliver, additional

Published
2023
Full Text
View/download PDF

28. Evaluation of ctDNA in patients with CRPC with pathogenic germline mutations in BRCA2.

Author

Huang, Minqi, primary, Jaeger, Ellen B., additional, Caputo, Sydney, additional, Casado, Crystal, additional, Jang, Albert, additional, Sweeney, Patrick L, additional, Lanka, Sree M, additional, Gupta, Kanika, additional, Lieberman, Alexandra, additional, Schwartz, Jennifer, additional, Pocha, Olivia, additional, Hawkins, Maddie, additional, Miller, Patrick, additional, Layton, Jodi Lyn, additional, Lewis, Brian E., additional, Barata, Pedro C., additional, Ledet, Elisa M., additional, and Sartor, A. Oliver, additional

Published
2023
Full Text
View/download PDF

29. Time interval between radium-223 (223Ra) therapy and Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) treatment and outcomes in the RALU study.

Author

Rahbar, Kambiz, primary, Essler, Markus, additional, Eiber, Matthias, additional, la Fougère, Christian, additional, Prasad, Vikas, additional, Pabst, Kim M., additional, Fendler, Wolfgang Peter, additional, Rassek, Philipp, additional, Hasa, Ergela, additional, Dittmann, Helmut, additional, Bundschuh, Ralph A., additional, Kurtinecz, Milena, additional, Schmall, Anja, additional, Verholen, Frank, additional, and Sartor, A. Oliver, additional

Published
2023
Full Text
View/download PDF

30. Evaluation of ctDNA in patients treated with lutetium-177-PSMA-617.

Author

Lanka, Sree M, primary, Jang, Albert, additional, Sweeney, Patrick L, additional, Gupta, Kanika, additional, Caputo, Sydney, additional, Casado, Crystal, additional, Huang, Minqi, additional, Pocha, Olivia, additional, Hawkins, Maddie, additional, Lieberman, Alexandra, additional, Schwartz, Jennifer, additional, Jaeger, Ellen B., additional, Miller, Patrick, additional, Layton, Jodi Lyn, additional, Barata, Pedro C., additional, Lewis, Brian E., additional, Ledet, Elisa M., additional, and Sartor, A. Oliver, additional

Published
2023
Full Text
View/download PDF

31. Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

Author

Clarke, Noel W., primary, Armstrong, Andrew J., additional, Thiery-Vuillemin, Antoine, additional, Oya, Mototsugu, additional, Shore, Neal D., additional, Procopio, Giuseppe, additional, Guedes, João Daniel Cardoso, additional, Arslan, Cagatay, additional, Mehra, Niven, additional, Parnis, Francis, additional, Brown, Emma, additional, Schlürmann, Friederike, additional, Joung, Jae Young, additional, Sugimoto, Mikio, additional, Sartor, A. Oliver, additional, Liu, Yu-Zhen, additional, Poehlein, Christian Heinrich, additional, Barker, Laura, additional, del Rosario, Paula Michelle, additional, and Saad, Fred, additional

Published
2023
Full Text
View/download PDF

32. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902

Author

Rosenthal, Seth A., Hunt, Daniel, Sartor, A. Oliver, Pienta, Kenneth J., Gomella, Leonard, Grignon, David, Rajan, Raghu, Kerlin, Kevin J., Jones, Christopher U., Dobelbower, Michael, Shipley, William U., Zeitzer, Kenneth, Hamstra, Daniel A., Donavanik, Viroon, Rotman, Marvin, Hartford, Alan C., Michalski, Jeffrey, Seider, Michael, Kim, Harold, Kuban, Deborah A., Moughan, Jennifer, and Sandler, Howard

Published
2015
Full Text
View/download PDF

33. 65. AR/enhancer alterations in metastatic castrate-resistant prostate cancer patient plasma predicts worse overall survival

Author

Chauhan, Pradeep, primary, Shiang, Alexander, additional, Dang, Ha, additional, Webster, Jace, additional, Ledet, Elisa, additional, Babbra, Ramandeep, additional, Feng, Wenjia, additional, Harris, Peter, additional, Qaium, Faridi, additional, Jaeger, Ellen, additional, Miller, Patrick, additional, Caputo, Sydney, additional, Santos, Giordano, additional, Pachynski, Russell, additional, Sartor, A. Oliver, additional, Maher, Christopher, additional, and Chaudhuri, Aadel, additional

Published
2022
Full Text
View/download PDF

34. Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race

Author

Zimmerman, Raquel, primary, Bilen, Mehmet A, additional, Heath, Elisabeth I, additional, Nandagopal, Lakshminarayanan, additional, Swami, Umang, additional, Kessel, Adam, additional, Jaeger, Ellen, additional, Wesolowski, Sergiusz, additional, Hernanadez, Edgar J, additional, Chipman, Jonathan, additional, Mack, Alleda, additional, Ravindranathan, Deepak, additional, Maughan, Benjamin L, additional, Nussenzveig, Roberto, additional, Yandell, Mark, additional, Kohli, Manish, additional, Lilly, Michael B, additional, Sartor, A Oliver, additional, Agarwal, Neeraj, additional, and Barata, Pedro C, additional

Published
2022
Full Text
View/download PDF

35. Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer.

Author

Morris, Michael J., primary, Sartor, A. Oliver, additional, Wong, Jeffrey Y.C., additional, Max, Steven I, additional, Xie, Hong, additional, Yu, Alex, additional, Divgi, Chaitanya R., additional, Patricia, Daniel, additional, Avadhani, Anjali Narayan, additional, Pandit-Taskar, Neeta, additional, Barata, Pedro C., additional, and Nordquist, Luke T., additional

Published
2022
Full Text
View/download PDF

36. Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study.

Author

James, Nicholas D., primary, Heinrich, Daniel, additional, Castro, Elena, additional, George, Saby, additional, Song, Daniel Y., additional, Dizdarevic, Sabina, additional, Baldari, Sergio, additional, Essler, Markus, additional, de Jong, Igle Jan, additional, Lastoria, Secondo, additional, Hammerer, Peter G., additional, Meltzer, Jeffrey, additional, Sandstrom, Per, additional, Verholen, Frank, additional, Tombal, Bertrand F., additional, O'Sullivan, Joe M., additional, and Sartor, A. Oliver, additional

Published
2022
Full Text
View/download PDF

37. [177Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial.

Author

Vaishampayan, Nitin, primary, Morris, Michael J., additional, Krause, Bernd J., additional, Vogelzang, Nicholas J., additional, Kendi, Ayse T., additional, Nordquist, Luke T., additional, Calais, Jeremie, additional, Nagarajah, James, additional, Beer, Tomasz M., additional, El-Haddad, Ghassan, additional, Brackman, Marcia, additional, Desilvio, Michelle, additional, Messmann, Richard Adam, additional, Sartor, A. Oliver, additional, and Fizazi, Karim, additional

Published
2022
Full Text
View/download PDF

38. Screening detects clinically significant hearing loss in patients with GU malignancies.

Author

Rauterkus, Grant, primary, Jang, Albert, additional, Jaeger, Ellen B., additional, Lieberman, Alex, additional, Sussman, Issabelle P., additional, Huang, Minqi, additional, Manogue, Charlotte, additional, Caputo, Sydney, additional, Washington, Whitney, additional, Lewis, Brian E., additional, Layton, Jodi Lyn, additional, Sartor, A. Oliver, additional, Jackson, Neal, additional, and Barata, Pedro C., additional

Published
2022
Full Text
View/download PDF

39. Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra): Interim analysis of the RALU study.

Author

Rahbar, Kambiz, primary, Essler, Markus, additional, Eiber, Matthias, additional, la Fougère, Christian, additional, Prasad, Vikas, additional, Fendler, Wolfgang P., additional, Rassek, Philipp, additional, Hasa, Ergela, additional, Dittmann, Helmut, additional, Bundschuh, Ralph A., additional, Pabst, Kim M., additional, Kurtinecz, Milena, additional, Sandstrom, Per, additional, Verholen, Frank, additional, and Sartor, A. Oliver, additional

Published
2022
Full Text
View/download PDF

42. Circulating tumor DNA responses to high-dose testosterone injections in CRPC patients.

Author

Caputo, Sydney, primary, Jaeger, Ellen B., additional, Fleming, William, additional, Manogue, Charlotte, additional, Huang, Minqi, additional, Lieberman, Alex, additional, Light, Malcolm, additional, Sussman, Isabelle P., additional, Miller, Patrick, additional, Barata, Pedro C., additional, Lewis, Brian E., additional, Layton, Jodi Lyn, additional, Ledet, Elisa M., additional, and Sartor, A. Oliver, additional

Published
2022
Full Text
View/download PDF

43. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Author

Gao, Xin, primary, Burris III, Howard A., additional, Vuky, Jacqueline, additional, Dreicer, Robert, additional, Sartor, A. Oliver, additional, Sternberg, Cora N., additional, Percent, Ivor John, additional, Hussain, Maha H. A., additional, Rezazadeh Kalebasty, Arash, additional, Shen, John, additional, Heath, Elisabeth I., additional, Abesada-Terk, Guillermo, additional, Gandhi, Sunil G., additional, McKean, Meredith, additional, Lu, Haolan, additional, Berghorn, Elmer, additional, Gedrich, Richard, additional, Chirnomas, S. Debbie, additional, Vogelzang, Nicholas J., additional, and Petrylak, Daniel P., additional

Published
2022
Full Text
View/download PDF

44. Longitudinal ctDNA alterations in germline positive CRPC patients.

Author

Huang, Minqi, primary, Jaeger, Ellen B., additional, Caputo, Sydney, additional, Fleming, William, additional, Light, Malcolm, additional, Manogue, Charlotte, additional, Sussman, Isabelle P., additional, Lieberman, Alex, additional, Lewis, Brian E., additional, Barata, Pedro C., additional, Layton, Jodi Lyn, additional, Ledet, Elisa M., additional, and Sartor, A. Oliver, additional

Published
2022
Full Text
View/download PDF

45. Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial.

Author

Nauseef, Jones T., primary, Thomas, Charlene, additional, Sun, Michael, additional, Sartor, A. Oliver, additional, Singh, Sharon, additional, Bissassar, Mahelia, additional, Fernandez, Escarleth, additional, Tan, Angela, additional, Patel, Amie, additional, Martinez Zuloaga, Juana, additional, Naiz, Muhammad Obaid, additional, Imad, Dunya, additional, Vallabhajosula, Shankar, additional, Molina, Ana M., additional, Sternberg, Cora N., additional, Nanus, David M., additional, Osborne, Joseph, additional, Bander, Neil Harrison, additional, Perk, Tim, additional, and Tagawa, Scott T., additional

Published
2022
Full Text
View/download PDF

46. 68ga-PSMA-11 patients with newly diagnosed and recurrent prostate cancer (Firefly).

Author

Manogue, Charlotte, primary, Rauterkus, Grant, additional, Light, Malcolm, additional, Sussman, Isabelle P., additional, Lieberman, Alex, additional, Huang, Minqi, additional, Davis, Gaynelle, additional, Barata, Pedro C., additional, Layton, Jodi Lyn, additional, Lewis, Brian E., additional, Harris, Kendra Marie, additional, Manning, Hailey, additional, and Sartor, A. Oliver, additional

Published
2022
Full Text
View/download PDF

47. Evaluation of ctDNA alterations in mCRPC patients with germline pathogenic mutations.

Author

Light, Malcolm, primary, Jaeger, Ellen B., additional, Caputo, Sydney, additional, Fleming, William, additional, Manogue, Charlotte, additional, Huang, Minqi, additional, Sussman, Isabelle P., additional, Lieberman, Alex, additional, Miller, Patrick, additional, Barata, Pedro C., additional, Layton, Jodi Lyn, additional, Lewis, Brian E., additional, Ledet, Elisa M., additional, and Sartor, A. Oliver, additional

Published
2022
Full Text
View/download PDF

48. Comparative ctDNA analyses of African-American and Caucasian patients with CRPC.

Author

Jaeger, Ellen B., primary, Caputo, Sydney, additional, Fleming, William, additional, Manogue, Charlotte, additional, Lieberman, Alex, additional, Sussman, Isabelle P., additional, Miller, Patrick, additional, Light, Malcolm, additional, Huang, Minqi, additional, Barata, Pedro C., additional, Lewis, Brian E., additional, Layton, Jodi Lyn, additional, Ledet, Elisa M., additional, and Sartor, A. Oliver, additional

Published
2022
Full Text
View/download PDF

49. Liquid biopsy AR/enhancer alteration detection before AR-targeted therapy and correlation with survival in metastatic castrate-resistant prostate cancer patients.

Author

Shiang, Alexander, primary, Chauhan, Pradeep S., additional, Dang, Ha X., additional, Webster, Jace, additional, Ledet, Elisa M., additional, Babbra, Ramandeep K, additional, Feng, Wenjia, additional, Harris, Peter K., additional, Jaeger, Ellen B., additional, Miller, Patrick, additional, Caputo, Sydney, additional, Cittolin Santos, Giordano Fabricio, additional, Pachynski, Russell Kent, additional, Sartor, A. Oliver, additional, Maher, Christopher, additional, and Chaudhuri, Aadel A, additional

Published
2022
Full Text
View/download PDF

50. Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).

Author

Nauseef, Jones T., primary, Thomas, Charlene, additional, Ho, Benedict, additional, Martinez Zuloaga, Juana, additional, Gonzalez, Brian D., additional, Sun, Michael, additional, Sartor, A. Oliver, additional, Singh, Sharon, additional, Bissassar, Mahelia, additional, Fernandez, Escarleth, additional, Tan, Angela, additional, Patel, Amie, additional, Naiz, Muhammad Obaid, additional, Vallabhajosula, Shankar, additional, Molina, Ana M., additional, Sternberg, Cora N., additional, Nanus, David M., additional, Osborne, Joseph, additional, Bander, Neil Harrison, additional, and Tagawa, Scott T., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results